| Dr Ramya Bhargava, MBBS | |
|
90 Presidential Plz # Firmc, Syracuse, NY 13202-2240 | |
| (315) 464-3834 | |
| Not Available |
| Full Name | Dr Ramya Bhargava |
|---|---|
| Gender | Female |
| Speciality | Nephrology |
| Experience | 23 Years |
| Location | 90 Presidential Plz # Firmc, Syracuse, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720501109 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 295137 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Univ. Dialysis Ctr @ Oswego | Oswego, NY | Dialysis facility |
| St Joseph's Hospital Health Center | Syracuse, NY | Hospital |
| University Hospital S U N Y Health Science Center | Syracuse, NY | Hospital |
| Crouse Hospital | Syracuse, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Department Of Medicine Medical Serv Grp At Suny Hlth Sci Ctr Syr In | 3274445796 | 242 |
| Nephrology Hypertension Associates Of Cny Pc | 4082513502 | 5 |
News Archive
Health Care REIT, Inc. today announced it has successfully completed its public offering of 29,900,000 shares of common stock at a price of $56.00 per share for total gross proceeds of approximately $1.7 billion. Total shares sold includes 3,900,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares.
Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.
Today Minnesota's leading health groups applauded Governor Tim Pawlenty for taking another step to protect youth from harmful tobacco products. This afternoon, the Governor signed into law the Tobacco Modernization and Compliance Act of 2010, which updates Minnesota laws to address new generations of tobacco products.
After the failure of cox II inhibitors such as Vioxx, osteoarthritis patients and their doctors are faced with a lack of alternative therapies. The Orthokine-therapy means knee-injections of IL-1Ra protein, obtained from the patient's blood.
Liquidia Technologies today announced it will receive approximately $3 million in funding from the U.S. Commerce Department's National Institute of Standards and Technology (NIST) to further develop and scale-up the company's PRINT manufacturing process.
› Verified 8 days ago
| Entity Name | Department Of Medicine Medical Serv Grp At Suny Hlth Sci Ctr Syr In |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063468239 PECOS PAC ID: 3274445796 Enrollment ID: O20031104000051 |
News Archive
Health Care REIT, Inc. today announced it has successfully completed its public offering of 29,900,000 shares of common stock at a price of $56.00 per share for total gross proceeds of approximately $1.7 billion. Total shares sold includes 3,900,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares.
Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.
Today Minnesota's leading health groups applauded Governor Tim Pawlenty for taking another step to protect youth from harmful tobacco products. This afternoon, the Governor signed into law the Tobacco Modernization and Compliance Act of 2010, which updates Minnesota laws to address new generations of tobacco products.
After the failure of cox II inhibitors such as Vioxx, osteoarthritis patients and their doctors are faced with a lack of alternative therapies. The Orthokine-therapy means knee-injections of IL-1Ra protein, obtained from the patient's blood.
Liquidia Technologies today announced it will receive approximately $3 million in funding from the U.S. Commerce Department's National Institute of Standards and Technology (NIST) to further develop and scale-up the company's PRINT manufacturing process.
› Verified 8 days ago
| Entity Name | Nephrology Hypertension Associates Of Cny Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760402564 PECOS PAC ID: 4082513502 Enrollment ID: O20040105000296 |
News Archive
Health Care REIT, Inc. today announced it has successfully completed its public offering of 29,900,000 shares of common stock at a price of $56.00 per share for total gross proceeds of approximately $1.7 billion. Total shares sold includes 3,900,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares.
Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.
Today Minnesota's leading health groups applauded Governor Tim Pawlenty for taking another step to protect youth from harmful tobacco products. This afternoon, the Governor signed into law the Tobacco Modernization and Compliance Act of 2010, which updates Minnesota laws to address new generations of tobacco products.
After the failure of cox II inhibitors such as Vioxx, osteoarthritis patients and their doctors are faced with a lack of alternative therapies. The Orthokine-therapy means knee-injections of IL-1Ra protein, obtained from the patient's blood.
Liquidia Technologies today announced it will receive approximately $3 million in funding from the U.S. Commerce Department's National Institute of Standards and Technology (NIST) to further develop and scale-up the company's PRINT manufacturing process.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ramya Bhargava, MBBS 90 Presidential Plz # Firmc, Syracuse, NY 13202-2240 Ph: (315) 464-3834 | Dr Ramya Bhargava, MBBS 90 Presidential Plz # Firmc, Syracuse, NY 13202-2240 Ph: (315) 464-3834 |
News Archive
Health Care REIT, Inc. today announced it has successfully completed its public offering of 29,900,000 shares of common stock at a price of $56.00 per share for total gross proceeds of approximately $1.7 billion. Total shares sold includes 3,900,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares.
Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.
Today Minnesota's leading health groups applauded Governor Tim Pawlenty for taking another step to protect youth from harmful tobacco products. This afternoon, the Governor signed into law the Tobacco Modernization and Compliance Act of 2010, which updates Minnesota laws to address new generations of tobacco products.
After the failure of cox II inhibitors such as Vioxx, osteoarthritis patients and their doctors are faced with a lack of alternative therapies. The Orthokine-therapy means knee-injections of IL-1Ra protein, obtained from the patient's blood.
Liquidia Technologies today announced it will receive approximately $3 million in funding from the U.S. Commerce Department's National Institute of Standards and Technology (NIST) to further develop and scale-up the company's PRINT manufacturing process.
› Verified 8 days ago
Courtney Myers, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 750 E Adams St Ste 311, Syracuse, NY 13210 Phone: 315-464-5815 | |
Joan Marie Mitchell, MD Nephrology Medicare: Medicare Enrolled Practice Location: 736 Irving Ave, Syracuse, NY 13210 Phone: 315-425-4828 Fax: 315-425-4827 | |
Gordana Obradovic, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1304 Buckley Rd, Suite 200, Syracuse, NY 13212 Phone: 315-478-3311 Fax: 315-476-5211 | |
Kristin A Ramella, NP Nephrology Medicare: Accepting Medicare Assignments Practice Location: 90 Presidential Plz Ste 5010, Syracuse, NY 13202 Phone: 315-464-9335 | |
Vinodhini M Subramanian, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 736 Irving Ave, Syracuse, NY 13210 Phone: 315-470-7111 | |
Robert R. Michiel, MD Nephrology Medicare: Medicare Enrolled Practice Location: 90 Presidential Plz, 5th Floor, Syracuse, NY 13202 Phone: 315-464-9335 Fax: 315-464-9338 | |
Michael P Gabris, MD FACC Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1000 E Genesee St, Suite 300, Syracuse, NY 13210 Phone: 315-471-1044 Fax: 315-474-4312 |